Modeling chemotherapy-induced peripheral neuropathy using a nerve-on-a-chip microphysiological systemPublications
July 15, 2020
Organ-on-a-chip devices that mimic in vivo physiology have the potential to identify effects of chemical and drug exposure in early preclinical stages of drug development while relying less heavily on animal models. We designed a hydrogel rat nerve-on-a-chip (RNoaC) construct that promotes axon growth analogous to mature nerve anatomy and is the first 3D in vitro model to collect electrophysiological and histomorphic metrics to assess in vivo pathophysiology. Nerve-on-a-chip is now known as NerveSim™.
Here we culture embryonic rat dorsal root ganglia (DRG) in the construct to demonstrate its potential to screen for implications of nerve dysfunction in chemotherapy-induced peripheral neuropathy (CIPN). RNoaC constructs containing DRG explants from E15 rat pups were exposed to the chemotherapeutics bortezomib, oxaliplatin, paclitaxel or vincristine for 7 days. Then, axons were electrically stimulated to collect nerve conduction velocity (NCV) and peak amplitude (AMP), which are clinical electrophysiological metrics indicative of healthy or diseased populations. All chemotherapeutics decreased NCV and AMP in a concentration-dependent manner. At high drug concentrations, NCV and AMP were 10-60% lower than control values. Histopathological analysis revealed hallmarks of peripheral neuropathy. IC50 values calculated from concentration-response curves indicate that the significant decrease in function occurred before a decrease in viability.
Our data suggest that electrophysiology recordings collected from our RNoaC platform can closely track subtle pathological changes in nerve function. The ability to collect clinically relevant data from RNoaC suggests it can be an effective tool for in vitro preclinical screening for peripheral neuropathy.
You can read the entire publication here.
AxoSim’s revolutionary NerveSim™, powered by Nerve-on-a-Chip® technology is the only in vitro model with high levels of Schwann cell myelination and human-relevant electrical and structural metrics, unlocking a powerful tool for human translation. Learn more about what makes NerveSim™ unique and how we predict clinical outcomes in the neurological drug discovery process. Interested in learning how you can use AxoSim’s proprietary NerveSim platform? Email us at email@example.com.